Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery

Scholarly Works

• Srivastava, V.; Godara, P.; Jena, S. P.; Naik, B.; Singh, S.; Prajapati, V. K.; Prusty, D. Peptide-ligand conjugate based immunotherapeutic approach for targeted dismissal of non-structural protein 1 of dengue virus: A novel therapeutic solution for mild and severe dengue infections. International journal of biological macromolecules 2024, 260, 129562. doi:10.1016/j.ijbiomac.2024.129562
• Fotie, J.; Matherne, C. M.; Mather, J. B.; Wroblewski, J. E.; Johnson, K.; Boudreaux, L. G.; Perez, A. A. The Fundamental Role of Oxime and Oxime Ether Moieties in Improving the Physicochemical and Anticancer Properties of Structurally Diverse Scaffolds. International journal of molecular sciences 2023, 24, 16854. doi:10.3390/ijms242316854
• Gomena, J.; Vári, B.; Oláh-Szabó, R.; Biri-Kovács, B.; Bősze, S.; Borbély, A.; Soós, Á.; Ranđelović, I.; Tóvári, J.; Mező, G. Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide-Drug Conjugates. International journal of molecular sciences 2023, 24, 3400. doi:10.3390/ijms24043400
• Singh, H.; Singh, R.; Dan, A.; Vithalani, H.; Das, S. S.; Fernando, A. V.; Vankayala, R.; Bhatia, D.; Dhanka, M. Bioconjugated materials as potential vehicles for delivery of antibiotics/drugs. Bioconjugated Materials Part 2 Applications in Drug Delivery, Vaccine Formulations and Important Conjugates for Cancer Therapy; Elsevier, 2023; pp 29–58. doi:10.1016/bs.coac.2023.03.003
• Godara, P.; Naik, B.; Meghwal, R.; Ojha, R.; Srivastava, V.; Prajapati, V. K.; Prusty, D. Rational designing of peptide-ligand conjugates-based immunotherapy for the treatment of complicated malaria. Life sciences 2022, 311, 121121. doi:10.1016/j.lfs.2022.121121
• Agnihotri, T. G.; Jadhav, G. S.; Sahu, B.; Jain, A. Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders. Drug delivery and translational research 2022, 12, 3104–3120. doi:10.1007/s13346-022-01173-y
• Schuster, S.; Juhász, É.; Halmos, G.; Neundorf, I.; Gennari, C.; Mező, G. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates. International journal of molecular sciences 2022, 23, 5071. doi:10.3390/ijms23095071
• Bharti, K.; Mishra, B. pH-Responsive Biomaterials in Drug Delivery. Functional Biomaterials; Springer Singapore, 2022; pp 37–74. doi:10.1007/978-981-16-7152-4_2
• Xu, L.; Xu, S.; Xiang, T.; Liu, H.; Chen, L.; Jiang, B.; Yao, J.; Zhu, H.; Hu, R.; Chen, Z. Multifunctional building elements for the construction of peptide drug conjugates. Engineered Regeneration 2022, 3, 92–109. doi:10.1016/j.engreg.2022.02.004
• Feni, L.; Neundorf, I. Different Approaches to Cyclize a Cell-Penetrating Peptide and to Tether Bioactive Payloads. Methods in molecular biology (Clifton, N.J.) 2021, 2371, 375–389. doi:10.1007/978-1-0716-1689-5_20
• Alas, M.; Saghaeidehkordi, A.; Kaur, K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. Journal of medicinal chemistry 2020, 64, 216–232. doi:10.1021/acs.jmedchem.0c01530
• Vrettos, E. I.; Karampelas, T.; Sayyad, N.; Kougioumtzi, A.; Syed, N.; Crook, T.; Murphy, C.; Tamvakopoulos, C.; Tzakos, A. G. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer. European journal of medicinal chemistry 2020, 211, 113018. doi:10.1016/j.ejmech.2020.113018
• Piorecka, K.; Smith, D. R. R.; Kurjata, J.; Stanczyk, M.; Stanczyk, W. A. Synthetic routes to nanoconjugates of anthracyclines. Bioorganic chemistry 2020, 96, 103617. doi:10.1016/j.bioorg.2020.103617
• Tripodi, A. A. P.; Ranđelović, I.; Biri-Kovács, B.; Szeder, B.; Mező, G.; Tóvári, J. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery. Pathology oncology research : POR 2019, 26, 1879–1892. doi:10.1007/s12253-019-00773-3
• Ranđelović, I.; Schuster, S.; Kapuvári, B.; Fossati, G.; Steinkühler, C.; Mező, G.; Tóvári, J. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice. International journal of molecular sciences 2019, 20, 4763. doi:10.3390/ijms20194763
• Pavlíčková, V.; Jurášek, M.; Rimpelová, S.; Záruba, K.; Sedlák, D.; Simkova, M.; Kodr, D.; Staňková, E.; Fähnrich, J.; Rottnerová, Z.; Bartůněk, P.; Lapčík, O.; Drašar, P.; Ruml, T. Oxime-based 19-nortestosterone-pheophorbide a conjugate: bimodal controlled release concept for PDT. Journal of materials chemistry. B 2019, 7, 5465–5477. doi:10.1039/c9tb01301f
• Lajkó, E.; Hegedüs, R.; Mező, G.; Kőhidai, L. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells. International journal of molecular sciences 2019, 20, 4421. doi:10.3390/ijms20184421
• Kiss, K.; Biri-Kovács, B.; Szabó, R.; Ranđelović, I.; Enyedi, K. N.; Schlosser, G.; Orosz, Á.; Kapuvári, B.; Tóvári, J.; Mező, G. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. European journal of medicinal chemistry 2019, 176, 105–116. doi:10.1016/j.ejmech.2019.05.016
• Schuster, S.; Biri-Kovács, B.; Szeder, B.; Buday, L.; Gardi, J.; Szabó, Z.; Halmos, G.; Mező, G. Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification. Pharmaceutics 2018, 10, 223. doi:10.3390/pharmaceutics10040223

Explore citations to this article at